Q-linea AB (SE:QLINEA)
:QLINEA
Want to see SE:QLINEA full AI Analyst Report?
QLINEA Stock Chart & Stats
kr29.00
>-kr0.01(-3.85%)
At close: 4:00 PM EST
kr29.00
>-kr0.01(-3.85%)
Day’s Range― - ―
52-Week Rangekr14.55 - kr74.06
Previous CloseN/A
Volume6.05M
Average Volume (3M)13.43K
Market Cap
kr323.07M
Enterprise Value-kr97.88M
Total Cash (Recent Filing)kr223.91M
Total Debt (Recent Filing)kr4.15M
Price to Earnings (P/E)―
Beta2.72
Next Earnings
Jul 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-20.75
Shares Outstanding18,949,081
10 Day Avg. Volume10,725
30 Day Avg. Volume13,430
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.49
Price to Sales (P/S)14.97
P/FCF Ratio-0.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.51
Revenue Forecast (FY)kr76.80M
Bulls Say, Bears Say
Bulls Say
Recurring Razor-and-blades Revenue ModelA razor-and-blades model creates durable recurring revenue from consumables tied to installed instruments. If instrument placements scale, predictable repeat consumable sales can improve gross margin sustainability, cash conversion and long-term revenue visibility independent of one-time instrument transfers.
Low Leverage And Restored EquityA modest debt load and strengthened equity position reduce solvency risk and provide financial flexibility over the medium term. This balance-sheet cushion lowers short-term refinancing pressure and supports continued R&D, commercialization investment, or strategic partnerships without immediate debt distress.
Structural Demand For Rapid AST And Sepsis DiagnosticsHealthcare demand for faster sepsis and AST diagnostics is structural due to antimicrobial resistance and hospital efficiency needs. A validated automated platform addressing this persistent clinical need can sustain long-term market opportunity and recurring consumable consumption as hospitals adopt rapid diagnostics workflows.
Bears Say
Large Cash Burn And Negative Operating Cash FlowVery high cash burn relative to revenue forces ongoing financing needs and raises risk of dilution or constrained investment. Persistent negative operating cash flow limits ability to scale sales, service installed base, or invest in commercialization over the next several months without external funding or meaningful revenue ramp.
Very Small And Declining Revenue BaseA tiny and shrinking revenue base undermines economies of scale for consumables and instrument placements. Limited top-line traction weakens margin recovery potential and prolongs the timeline to positive cash generation, making the business highly sensitive to execution delays and commercialization setbacks.
Deeply Negative Profitability And Gross LossNegative gross profit signals structural cost or pricing issues at current volumes, not just transient operating expenses. Persistent deep losses erode equity over time and require either significant volume scale, pricing adjustments, or cost restructuring to restore margins and a credible path to sustainable profitability.
Q-linea AB News
QLINEA FAQ
What was Q-linea AB’s price range in the past 12 months?
Q-linea AB lowest stock price was kr14.55 and its highest was kr74.06 in the past 12 months.
What is Q-linea AB’s market cap?
Q-linea AB’s market cap is kr323.07M.
When is Q-linea AB’s upcoming earnings report date?
Q-linea AB’s upcoming earnings report date is Jul 10, 2026 which is in 18 days.
How were Q-linea AB’s earnings last quarter?
Q-linea AB released its earnings results on Apr 30, 2026. The company reported -kr1.772 earnings per share for the quarter, missing the consensus estimate of N/A by -kr1.772.
Is Q-linea AB overvalued?
According to Wall Street analysts Q-linea AB’s price is currently Overvalued.
Does Q-linea AB pay dividends?
Q-linea AB does not currently pay dividends.
What is Q-linea AB’s EPS estimate?
Q-linea AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Q-linea AB have?
Q-linea AB has 18,949,081 shares outstanding.
What happened to Q-linea AB’s price movement after its last earnings report?
Q-linea AB reported an EPS of -kr1.772 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.371%.
Which hedge fund is a major shareholder of Q-linea AB?
Currently, no hedge funds are holding shares in SE:QLINEA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Q-linea AB
Q-linea AB (publ), founded in 2008 and based in Uppsala, Sweden, specializes in developing diagnostic instruments and associated consumables for infection detection. The company crafts advanced in vitro diagnostic platforms, specifically engineered to identify infectious diseases. A key product is ASTar, an innovative system designed to rapidly assess antibiotic susceptibility in positive blood cultures. Q-linea's overarching mission is to deliver cutting-edge solutions to healthcare professionals.
Technical Analysis
Vicore Pharma Holding AB
―
Isofol Medical AB
―
Biovica International AB Class B
―
Doxa AB
―
Guard Therapeutics International AB
―